An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 1-7

  Sandler, Alan ^a   Hirsh, Vera ^b   Reck, Martin ^c   von Pawel, Joachim ^d   Akerley, Wallace ^e   Johnson, David H ^f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti VEGF therapy; Bevacizumab; Brain metastases; CNS hemorrhage; CNS metastases; NSCLC

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; ERLOTINIB; GEMCITABINE; MOTESANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN INHIBITOR;

ANTIANGIOGENIC THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN METASTASIS; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CONVULSION; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL STROMAL TUMOR; GRAND MAL SEIZURE; HUMAN; INCIDENCE; INOPERABLE CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MENTAL DISEASE; METASTATIC MELANOMA; MOTOR NEUROPATHY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INCIDENCE; INTRACRANIAL HEMORRHAGES; LUNG NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866144231     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.07.004     Document Type: Review

References (51)

1. Lassman A.B., DeAngelis L.M. Brain metastases. Neurol Clin 2003, 21:1-23.
2. Langer C.J., Mehta M.P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005, 23:6207-6219.
3. Mintz A., Perry J., Spithoff K., Chambers A., Laperriere N. Management of single brain metastasis: a practice guideline. Curr Oncol 2007, 14:131-143.
4. Eichler A.F., Loeffler J.S. Multidisciplinary management of brain metastases. Oncologist 2007, 12:884-898.
5. Komaki R., Cox J.D., Stark R. Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. Int J Radiat Oncol Biol Phys 1983, 9:1467-1470.
6. Sørensen J.B., Hansen H.H., Hansen M., Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988, 6:1474-1480.
7. Srivastava G., Rana V., Wallace S., Taylor S., Debnam M., Feng L., et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol 2009, 4:333-337.
8. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5-14.
9. Salmaggi A., Erbetta A., Silvani A., Maderna E., Pollo B. Intracerebral haemorrhage in primary and metastatic brain tumours. Neurol Sci 2008, 29(Suppl. 2):S264-S265.
10. Mandybur T.I. Intracranial hemorrhage caused by metastatic tumors. Neurology 1977, 27:650-655.
11. Bitoh S., Hasegawa H., Ohtsuki H., Obashi J., Fujiwara M., Sakurai M. Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol 1984, 22:57-62.
12. Murakami K., Nawano S., Moriyama N., Sekiguchi R., Satake M., Fujimoto H., et al. Intracranial metastases of hepatocellular carcinoma: CT and MRI. Neuroradiology 1996, 38(Suppl. 1):S31-S35.
13. Carden C.P., Larkin J.M., Rosenthal M.A. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol 2008, 10:624-630.
14. Kidwell C.S., Chalela J.A., Saver J.L., Starkman S., Hill M.D., Demchuk A.M., et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004, 292:1823-1830.
15. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972, 175:409-416.
16. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-1795.
17. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002, 29(Suppl. 16):10-14.
18. Fontanini G., Boldrini L., Chine S., Pisaturo F., Basolo F., Calcinai A., et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 1999, 79:363-369.
19. Han H., Silverman J.F., Santucci T.S., Macherey R.S., d'Amato T.A., Tung M.Y., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001, 8:72-79.
20. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001, 19:432-441.
21. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
22. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234.
23. F. Hoffmann-La Roche Ltd. Avastin (bevacizumab) summary of product characteristics. Available at: (accessed 06.07.11). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf.
24. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007, 13:1367-1373.
25. Pouessel D., Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008, 53:376-381.
26. Nguyen T., DeAngelis L.M. Treatment of brain metastases. J Support Oncol 2004, 2:405-416.
27. Gordon M.S., Margolin K., Talpaz M., Sledge G.W., Holmgren E., Benjamin R., et al. Phase I, safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
28. Oh Y., Wallace S., Taylor S., Herbst R.S., Lippman S.M., Karp D.D., et al. Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies. J Clin Oncol 2008, 26(Suppl. 15 Pt I):628s. [abstr 14507].
29. Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010, 16:269-278.
30. Scappaticci F.A., Skillings J.R., Holden S.N., Gerber H.P., Miller K., Kabbinavar F., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
31. F. Hoffmann-La Roche Ltd. Investor Update 31/03/09. Avastin label updated reflecting confidence in safety profile. Available at: (accessed 06.07.11). http://www.roche.com/investors/ir_update/inv-update-2009-03-31.htm.
32. Archer V., Reck M., Sandler A.B., Johnson D.H., Kong G., Strickland D.K., et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with nonsquamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. J Clin Oncol 2008, 26(Suppl. 15 Pt I):452s. [abstr 8114].
33. DeBraganca K.C., Ney D.E., Kris M.G., Nolan C.P., Lassman A.B. Bevacizumab for active brain metastases from non-small cell lung cancer. Proceedings from the 2009 joint meeting of SNO and AANS/CNS section on tumors neuro-oncology 2009, [abstr 272].
34. Heist R.S., Fidias P., Huberman M., Ardman B., Sequist L.V., Temel J.S., et al. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:1153-1158.
35. Socinski M.A., Langer C.J., Huang J.E., Kolb M.M., Compton P., Wang L., et al. Safety of bevacizumab in patients with non-small cell lung cancer and brain metastases. J Clin Oncol 2009, 27:5255-5261.
36. Akerley W., Langer C., Oh Y., Strickland D.K., Joo Royer S., Xia Q., et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. J Clin Oncol 2008, 26(Suppl. 15 Pt I):434s. [abstr 8043].
37. Miller V.A., O'Connor P., Soh C., Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2009, 27(Suppl. 18 Pt II):799s. for the ATLAS Investigators, [abstr LBA8002].
38. Crinò L., Dansin E., Garrido P., Griesinger F., Laskin J., Pavlakis N., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010, 11:733-740.
39. Tsai C.M., Griesinger F., Laskin J., Crinò L., Pavlakis N., Dansin E., et al. Low incidence of grade≥3 bleeding events and low discontinuation rates associated with first line bevacizumab (bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study. Eur J Cancer Suppl 2009, 7:557-558. [abstr 9171].
40. Jahanzeb M., Fischbach N., Kosty M., Kumar P., Spigel D., Wozniak A., et al. Safety of bevacizumab (BV) combined with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC): interim results from the ARIES lung observational cohort study. Eur J Cancer Suppl 2009, 7:506. [abstr 9006].
41. Lynch T.J., Brahmer J., Fischbach N., Garst J., Kumar P., Spigel D.R., et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS). J Clin Oncol 2008, 26(Suppl. 15 Pt I):443s. [abstr 8077].
42. Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:650-656.
43. Novello S., Camps C., Grossi F., Mazieres J., Abrey L., Fain J., et al. Safety and efficacy of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. Eur J Cancer Suppl 2009, 7:551. [abstr P-9153].
44. Scagliotti G.V., Krzakowski M., Szczesna A., Strausz J., Makhson A., Reck M., et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012, 30:2070-2078.
45. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
46. Gutierrez M., Kummar S., Allen D., Turkbey B., Choyke P., Wright J.J., et al. A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26(Suppl. 15 Pt I):712s. [abstr 19084].
47. Blumenschein G., Gatzemeier U., Fossella F., Stewart D.J., Cupit L., Cihon F., et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:4274-4280.
48. Dy G.K., Hillman S.L., Rowland K.M., Molina J.R., Steen P.D., Wender D.B., et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer 2010, 116:5686-5693.
49. Tamaskar I., Garcia J.A., Elson P., Wood L., Mekhail T., Dreicer R., et al. Antitumour effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008, 179:81-86.
50. Stadler W.M., Figlin R.A., McDermott D.F., Dutcher J.P., Knox J.J., Miller W.H., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280.
51. Amaravadi R.K., Schuchter L.M., McDermott D.F., Kramer A., Giles L., Gramlich K., et al. Phase II, trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15:7711-7718.